Dr Christopher Trethewey

University of Cambridge
Cambridge University Hospitals NHS Foundation Trust

University departments: 
Department of Oncology
University institutes: 
CRUK Cambridge Institute
NHS or other affiliations: 
Cancer Molecular Diagnostics Laboratory

Position: Clinical Research Associate
Personal home page: https://pubmed.ncbi.nlm.nih.gov/?term=Trethewey+CS
Email:   cst39@medschl.cam.ac.uk

PubMed journal articles - click here

Research Programme or Virtual Institute: 
Not applicable
Secondary Programme: 
Haematological Malignancies Virtual Institute
Strategic Resources: 
Cancer Molecular Diagnostics Laboratory
Methods and technologies: 
Bioinformatics
Clinical trials
DNA sequencing
Genomics
PCR
Tumour type interests: 
Non-Hodgkin lymphoma
cst39
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge


Key publications: 

2024, eJHaem. Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma

Abdullah N. M. Alqahtani, Sandrine Jayne, Matthew J. Ahearne, Christopher S. Trethewey, Sai S. Duraisingham, Susann Lehmann, Caroline M. Cowley, Martin J. S. Dyer, Harriet S. Walter

https://doi.org/10.1002/jha2.966

2023, Leicester. Molecular profiling of circulating tumour DNA in aggressive lymphoid malignancies

Christopher S. Trethewey, PhD thesis.

https://doi.org/10.25392/leicester.data.23966973.v1

https://figshare.le.ac.uk/articles/thesis/Molecular_Profiling_of_Circulating_Tumour_DNA_in_Aggressive_Lymphoid_Malignancies/23966973

2023, Blood Advances. BTK mutations in patients with chronic lymphocytic leukemia (CLL) receiving tirabrutinib

2023, Blood Advances. DOI: 10.1182/bloodadvances.2022009366

Ross A Jackson, Robert Graham Britton, Sandrine Jayne, Susann Lehmann, Caroline M Cowley, Christopher Simon Trethewey, Victoria M Smith, Ralf Schmid, Christopher Fegan, Harriet Sarah Walter, Martin JS Dyer

2022, Hemasphere. Limitations of Monitoring Disease Progression Using Circulating Tumor DNA in Lymphoma: An Example From Primary Cutaneous DLBCL Leg-type.

https://doi.org/10.1097/HS9.0000000000000690

Christopher S Trethewey, Harriet S Walter, Abdullah N M Alqahtani, Ralf Schmid, David S Guttery, Yvette Griffin, Matthew J Ahearne, Gerald S Saldanha, Sandrine P N Jayne, Martin J S Dyer

2020, Blood Advances. Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma. 

https://doi.org/10.1182/bloodadvances.2019001075

Ottolini B, Nawaz N, Trethewey CS, Mamand S, Allchin RL, Dillon R, Fields PA, Ahearne MJ, Wagner SD. Blood Adv. 2020

2019, JCO Precision Oncology. Successful Treatment of Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type With Single-Agent Venetoclax.

https://doi.org/10.1200/PO.19.00002

Walter S, Trethewey CS, Ahearne MJ, Jackson R, Jayne S, Wagner SD, Saldanha G, Dyer JS. JCO Precision 

Molecular profiling by CAPP-Seq of baseline cfDNA obtained from 13 primary DLBCL cases.